StreetAlpha.app
Home › Stocks › NTLA

Intellia Therapeutics, Inc. (NTLA)

Healthcare
$9.78
▼ −0.81%
LAST CLOSE · NOV 17

Intellia develops CRISPR gene editing treatments for severe diseases, with lead candidates in late stage clinical trials. It last closed at $9.78 on Nov 17, down 0.81% on the day. The average 12-month price target from 3 analysts is $15.33 (+56.8% from the last close), with a high of $25.00 and a low of $8.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 1 hold, 1 sell).

AI Auto Pilots
Is NTLA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$52.9M
−8.1% vs a year ago
Net income
−$426.1M
−805.7% margin
EPS (diluted)
−$3.35
Free cash flow
−$358.1M
−677.1% margin
Valuation
Market cap
$1.4B
140.4M shares
P/E
–
No P/E while losing money
Price to sales
26.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$156.1M
At Sep 30
Debt
$73.7M
At Sep 30
Shareholder equity
$613.1M
Shares outstanding
140.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $33.1M$33.1MFY2021FY2022: $52.1M$52.1MFY2022FY2023: $36.3M$36.3MFY2023FY2024: $57.9M$57.9MFY2024FY2025: $67.7M$67.7MFY2025

From NTLA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
1 Buy1 Hold1 Sell
Each firm's latest rating on NTLA in the past 90 days
Average 12-month target
$15.33
▲ 56.8% upside

Based on 3 analysts who set a price target on NTLA in the past 90 days. The average target is $15.33, with a high of $25.00 and a low of $8.00, compared with the last close of $9.78.

$7$13$20$26PAST 11 TRADING DAYS12-MONTH TARGETSHIGH $25AVG $15.33LOW $8Jun 4LAST CLOSE+12 MO$7$13$20$26PAST 11 DAYSTARGETSHIGH $25AVG $15.33LOW $8Jun 4LAST CLOSE+12 MO
Highest target$25.00
Average target$15.33
Lowest target$8.00
Latest rating changes
BarclaysInitiated
Oct 6Sell$8
WedbushTarget lowered
Sep 9Hold$17 → $13
HC Wainwright & Co.Reiterated
Sep 9Buy$25
Evercore ISI GroupUpgrade
Aug 7Buy$24
Wolfe ResearchDowngrade
Jul 16Sell$9
DateFirmActionRatingPrice target
Oct 6BarclaysInitiatedSell$8
Sep 9WedbushTarget loweredHold$17 → $13
Sep 9HC Wainwright & Co.ReiteratedBuy$25
Aug 7Evercore ISI GroupUpgradeBuy$24
Jul 16Wolfe ResearchDowngradeSell$9
Loading…

Technical Analysis

NTLA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 17% below its 20 day and 21% below its 50 day average. It is 32% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $9.56, and the nearest resistance the Pivot at $9.90.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$18.4852 week high+89.0%
$12.92200 day average+32.1%
$12.32100 day average+26.0%
$12.00Swing high (Oct 20)+22.7%
$11.8050 day average+20.7%
$11.4720 day average+17.3%
$10.12Pivot R1+3.5%
$9.90Pivot+1.2%
$9.78Last close
$9.56Pivot S1−2.2%
$7.9552 week low−18.7%
Indicators
RSI (14)37.33Weak, oversold below 30Neutral
MACD-0.51Below its signal lineBearish
Stochastic2.6Near the bottom of its rangeOversold
ADX (14)13.7No clear trend
Williams %R-97.4Oversold below −80, overbought above −20Oversold
CCI (20)-153.8Oversold below −100, overbought above 100Oversold
Rate of change−17.5%Change over 10 sessionsBearish
ATR (14)$0.82Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NTLA

What happened before

See how NTLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NTLA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NTLA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NTLA in the last 90 days.

Loading…

See today’s whale options flow across the market →

NTLA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●154 buying vs 140 selling
  • ▼Held by funds -6.7 pts
  • ▼Funds holding -17
  • ▼Superinvestors: 1 added, 5 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding313330−5.2%
In funds' top 1012−50.0%
Held by funds96.4%103.1%−6.7 pts
New / increased35 / 11952 / 139−19.4%
Reduced / sold out90 / 5083 / 29+25.0%
Put/call ratio0.200.19+0.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NTLA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTLA is in one of them and how their past NTLA trades turned out.

NTLA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NTLA in an article yet. Here's the latest on the wider market.

NTLA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Sep 5
Who traded NTLA · since 2017
Latest 5 filings of 15
$1K – $15KTraded Aug 25, 2023Filed Sep 5, 2023
$1K – $15KTraded May 22, 2023Filed Jun 30, 2023
$15K – $50KTraded Feb 28, 2022Filed Mar 3, 2022
$1K – $15KTraded Oct 29, 2021Filed Oct 30, 2021
$1K – $15KTraded Sep 20, 2021Filed Oct 1, 2021
PersonTypeAmountTradedFiledDelay
Tom CarperD · DESell$1K – $15KAug 25, 2023Sep 5, 202311 d
Tom CarperD · DEBuy$1K – $15KMay 22, 2023Jun 30, 202339 d
Don BeyerD · VASell$15K – $50KFeb 28, 2022Mar 3, 20223 d
Don BeyerD · VASell$1K – $15KOct 29, 2021Oct 30, 20211 d
Don BeyerD · VASell$1K – $15KSep 20, 2021Oct 1, 202111 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Intellia Therapeutics

Intellia is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments using CRISPR gene editing. Its lead candidates are designed to address the underlying cause of rare, severe diseases, including hereditary angioedema and ATTR amyloidosis, and are given as a single intravenous infusion. The company's lead candidates are in late stage clinical trials, and it is preparing for possible commercial launches aimed at patients with these conditions. It also works with partners, such as Regeneron, on additional programs.

Headquarters
Cambridge, MA
Founded
2014